Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas
about
The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem CellsGene rearrangement: a novel mechanism for MDR-1 gene activationImpact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.Current and emerging therapies for advanced adrenocortical carcinoma.Current and emerging therapeutic options in adrenocortical cancer treatment.Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.[Treatment of childhood adrenocortical tumor].Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.Role of Mitotane in Adrenocortical Carcinoma - Review and State of the artATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
P2860
Q28550040-C15D0DA2-9279-480A-ABB6-B5C9C58F4F34Q34422183-146D6A14-A796-4FEA-8559-2C4F740F1868Q34519879-EE16A522-6C1C-4AF5-AD45-637FE3134D2AQ35584305-0607C845-DEDC-4DE3-93AE-81F5B1CCE2AAQ36183873-B4769C48-6216-4C67-A428-DD8274282453Q36391073-CAD88134-C85C-427A-B112-353B1C75546BQ37010772-01F92503-4CAA-411E-A839-514C0064787DQ37924869-4D8B9B7C-7AD0-4A0C-A485-FC391ACFF360Q37924953-3D8F68A1-7E3C-48A3-9F0A-B3ACA64092E4Q37967559-29D1D0F4-88F2-49F5-B795-3DA63CDD01A2Q38545507-C98F34FE-C7F0-4275-A6AF-3168F7D83C51Q38925278-EE09C919-B56A-4744-90B7-2F0631DA0639Q38968381-F5BE7793-AA2E-4D66-9B4B-9807D5840A50Q46917436-594452E8-553A-4237-857C-F2A3D3F3FD6BQ51795765-DE7166F5-78FB-499B-81A5-CA5AEE89A172Q57822726-9915731E-B28C-4873-8D90-A648CCFBE643Q58798114-825F8D21-B2DE-4763-8858-C491C34B0FD4
P2860
Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas
description
1991 nî lūn-bûn
@nan
1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@ast
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@en
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@nl
type
label
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@ast
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@en
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@nl
prefLabel
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@ast
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@en
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@nl
P2093
P921
P356
P1476
Mitotane enhances cytotoxicity ...... d by adrenocortical carcinomas
@en
P2093
D L Loriaux
H L Dichek
L A Mickley
P356
10.1210/JCEM-73-1-18
P407
P577
1991-07-01T00:00:00Z